ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses (Adv. Mater. 14/2024)

ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses (Adv. Mater. 14/2024)

SARS‐CoV‐2 In article number 2311537 by Jincun Zhao, Xun Sun, and co‐workers, a specific ACE2‐binding peptide with a superior antiviral activity was identified and used to modified the inhaled nanoemulsions. The inhaled remdesivir nanoemulsions strongly inhibit SARS‐CoV‐2 not only by blocking the bi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Weinheim) 2024-04, Vol.36 (14), p.n/a
Hauptverfasser: Wang, Hairui, Luo, Shuang, Xie, Mingxin, Chen, Zhao, Zhang, Yunming, Xie, Zhiqiang, Zhang, Yongshun, Zhang, Yu, Yang, Lan, Wu, Fuhua, Chen, Xiaoyan, Du, Guangsheng, Zhao, Jincun, Sun, Xun
Format: Artikel
Sprache:eng
Schlagworte:
ACE2‐binding peptide
Binding
COVID‐19
inhalation
Nanoemulsions
SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2)
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SARS‐CoV‐2 In article number 2311537 by Jincun Zhao, Xun Sun, and co‐workers, a specific ACE2‐binding peptide with a superior antiviral activity was identified and used to modified the inhaled nanoemulsions. The inhaled remdesivir nanoemulsions strongly inhibit SARS‐CoV‐2 not only by blocking the binding of virus to host cells at the cell surface but also restricting virus replication intracellularly.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202470103